What Happened to Genus plc Shares on 13 November 2026?

Genus plc (LSE:GNS) shares eased 1.13% to 2,268.0p on 13 November 2026. The animal genetics group was in focus following its preliminary results for the year ended 30 June 2026, published on 10 September 2026.

The results reported higher adjusted profit and cash generation, a larger Dividend and a £60m share buyback programme.

Key Highlights

Adjusted profit before tax rose 35% to £100.2m, and adjusted Earnings Per Share rose 35% to 110.3p. The final dividend rose 11% to 24.0p, taking the full-year dividend to 35.2p, up 10%.

The £60m buyback is to be completed during FY27, and free Cash Flow was £62.0m, up 52%.

About Genus plc

Genus plc is an animal genetics company operating through ABS, which focuses on bovine genetics, and PIC, which focuses on porcine genetics. Its R&D team supports both businesses.

Jorgen Kokke is Chief Executive and Andy Russell is Chief Financial Officer. The Annual General Meeting is scheduled for 18 November 2026.

PIC Performance

PIC's adjusted operating profit rose 17%, and volumes including joint ventures increased 12%. The company said PIC performed well in every region, supported by higher Royalty Revenue and joint venture contributions in Brazil and China.

PIC's estimated Market Share in China rose to 5.4% from 3.4% in the prior year.

China Joint Venture

In January 2026 Genus formed a strategic porcine joint venture in China with Beijing Capital Agribusiness to accelerate the long-term opportunity for PIC. The company disposed of 51% of PIC China, and net proceeds were £97.7m, which strengthened the balance sheet.

Group revenue of £658.1m reflects the deconsolidation of PIC China from 31 January 2026.

ABS and PRP Progress

ABS Volume rose 1%, including 2% growth in sexed volume. For the PRRS-resistant pig, approvals or positive determinations were secured in Argentina, Canada, Uruguay and other countries.

Management is looking to commercialise the gene-edited pig once regulatory approval is gained in certain markets.

Outlook

Genus expects FY27 adjusted profit before tax to be in line with market expectations and moderately above the normalised FY26 figure of £90.3m. Moderate adjusted operating profit growth is expected from both PIC and ABS, with earnings weighted to the second half.

The dividend payout was 32% of adjusted earnings per share, within the company's 30% to 40% policy.

Understanding Genetics Royalties and Joint Ventures

Animal genetics companies earn revenue from supplying breeding stock and semen, and from royalties based on the performance of the animals produced. A joint venture shares ownership with a local partner, which can help access a market.

PRRS is a viral disease affecting pigs, and a resistant pig is designed to reduce its impact.

Why the Update Matters for the Sector

Animal genetics is followed for how breeding innovation can support efficient protein production. Genus's results show how scale in porcine and bovine genetics supports cash generation.

Regulatory approvals for gene editing are an important sector theme.

Putting the Update in Context

Healthcare and life sciences companies are commonly followed for product pipelines, regulatory milestones, customer contracts and the way capital is allocated to development and capacity. Updates often describe progress against development timelines and commercial agreements.

Revenue in these businesses can include product sales, service fees and milestone payments, and companies explain how each is recognised. Cash balances and funding runway are routine parts of reporting, helping readers understand how programmes are supported.

Key Growth Catalysts

Growth in PIC, the China joint venture, ABS efficiency gains and PRP approvals are the main supports. Cash generation funds the dividend and the share buyback.

A lower Leverage position adds flexibility.

Factors to Monitor

Livestock prices, currency movements, disease risks and regulatory timelines influence results. Approval of gene-edited products depends on the decisions of authorities in each market.

Earnings are expected to be weighted to the second half of FY27.

What Investors Should Watch Next

Investors may wish to follow the annual general meeting on 18 November 2026, buyback progress, PRP approvals, China market share and FY27 trading updates.

Conclusion

Genus plc (LSE:GNS) eased 1.13% to 2,268.0p on 13 November 2026. Genus reported a 35% rise in adjusted profit before tax, a 10% higher dividend and a £60m buyback. The annual general meeting is the next point of reference.